HanchorBio Reports High Objective Response Rate with HCB101 Combination in   Second-Line Gastric Cancer Following ASCO-GI 2026 Poster Presentation Mid-dose cohorts demonstrate ~80% ORR when HCB101 is layered on the standard ramucirumab and paclitaxel in second-line gastric cancer. HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today […]

HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.